FDA published “Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment” Guidance for Industry

FDA.jpeg

Today, the Food and Drug Administration published “Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment” Guidance for Industry. Guidances such as these are reflective of the agency's current thinking on this topic. Jett Foundation hopes that this guidance will encourage further drug development in Duchenne, and provide a clearer path towards the FDA approval of safe and effective treatments that improve and extend the lives of children and young people living with Duchenne. 

Read more: Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry